Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of fenfluramine oral solution in rare seizure disorders
2019-001331-31Phase 3Unknown
- Sponsor
- Zogenix, Inc.
- Start
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of fenfluramine in Dravet syndrome, Lennox-Gastaut syndrome (LGS) and epileptic encephalopathy, sponsored by Zogenix, Inc. Primary endpoint: Long-term safety and tolerability of ZX008. Status: unknown.
02
Drugs
fenfluramine
03
Conditions
Dravet syndromeLennox-Gastaut syndrome (LGS)epileptic encephalopathy
Beyond the preview
Go deeper on 2019-001331-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001331-31.